Nasreen Nakad

Mrs. Nasreen Nakad

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NNNasreen Nakad
Nasreen Nakad
Fuad FaresFuad Fares
Fuad Fares
Thyrostimulin is a heterodimeric glycoprotein hormone composed of two subunits, GPA2 and GPB5, first identified in 2002. It is considered an ancestral member of the glycoprotein hormone family and is highly conserved across species, including vertebrates and invertebrates. Unlike classical pituitary glycoprotein hormones such as TSH, LH, and FSH, thyrostimulin appears to function predominantly through paracrine and autocrine mechanisms, with its expression reported in diverse tissues such as the pituitary, ovary, skin, and brain. In humans, thyrostimulin has been implicated in ovarian cancer cell proliferation, stem cell quiescence in the pituitary, and metabolic regulation. However, its role in metabolism remains unclear, with studies showing both beneficial and adverse effects such as weight loss in some models and elevated levels in polycystic ovary syndrome and metabolic syndrome patients. In Caenorhabditis elegans, orthologs of GPA2 and GPB5 have been shown to influence growth and intestinal function via a neuroendocrine pathway involving thyrotropin hormone-like peptides. These findings suggest that thyrostimulin has conserved multifunctional roles in development, metabolism, and endocrine signaling. The aim of this review is to summarize the structure–function relationships and the currently known roles of thyrostimulin and its subunits, GPA2/GPB5, particularly in the reproductive system, metabolic syndrome, skeletal development, and obesity.

Verified
Journal Article
Open access
PDF file
NNNasreen Nakad
Nasreen Nakad
RBRinat Bar-Shalom
Rinat Bar-Shalom
NANaiel Azzam
Naiel Azzam
Fuad FaresFuad Fares
Fuad Fares
Glycoprotein hormone receptors are G-protein-coupled receptors essential for endocrine signaling. Thyroid-stimulating hormone receptor (TSHR), originally expressed in the thyroid gland, has been increasingly detected in various normal and malignant tissues, suggesting a wide range of functions. We hypothesized that extrathyroidal TSHR contributes to tumor development and activation via local stimulators such as thyrostimulin and its subunits. In the present study, TSHR expression was characterized in breast (T47D, MCF7), pancreatic (PL45, BXPC3), and colon (HCT116) cancer cell lines using quantitative real-time PCR, immunohistochemistry, and Western blotting. The sequencing of the TSHR cDNA revealed several novel mutations with potential functional relevance. Notably, missense mutations, Glu362Asp (PL45, HCT116) and Ala380Pro (T47D) were identified in the extracellular hinge region, which is a key domain for ligand binding and receptor activation. Functional interpretation suggests that Glu362Asp may lower the steric barrier, thereby enhancing the receptor sensitivity to non-canonical ligands such as thyrostimulin. In addition, Ile419Leu identified in T47D cells and located within the transmembrane Helix 1 may alter receptor conformation and signaling capacity. Consistent with these findings, variable proliferative responses to bovine thyroid-stimulating hormone (bTSH) were observed across the examined cell lines. Collectively, these results functionally identify relevant TSHR variants in cancer cells and support a model in which extrathyroidal TSHR signaling contributes to tumor progression. Targeting these receptors may represent a novel therapeutic approach.